Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled to take place in New York, NY on September 10, 2024.
Key points:
- Management will present at 11:30 am ET
- One-on-one meetings will be held
- A live and recorded webcast will be available on the company's website
This conference provides Senseonics an opportunity to showcase its innovative CGM technology and engage with potential investors, potentially impacting the SENS stock.
Positive
- None.
Negative
- None.
News Market Reaction – SENS
On the day this news was published, SENS gained 4.78%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference, being held in New York, NY.
Management is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET and will hold one-on-one meetings.
Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
Investors@senseonics.com
FAQ
When is Senseonics Holdings (SENS) participating in the H.C. Wainwright Global Investment Conference?
What time is Senseonics Holdings (SENS) scheduled to present at the conference?
Where can investors access the webcast of Senseonics Holdings' (SENS) presentation?
What is the main focus of Senseonics Holdings (SENS) as a medical technology company?
